Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open …
JB Vermorken, J Stöhlmacher-Williams… - The lancet …, 2013 - thelancet.com
Background Previous trials have shown that anti-EGFR monoclonal antibodies can improve
clinical outcomes of patients with recurrent or metastatic squamous-cell carcinoma of the …
clinical outcomes of patients with recurrent or metastatic squamous-cell carcinoma of the …
Cisplatin-based chemotherapy options for recurrent and/or metastatic squamous cell cancer of the head and neck
KP Pendleton, JR Grandis - Clinical Medicine Insights …, 2013 - journals.sagepub.com
Recurrent and/or metastatic head and neck squamous cell carcinoma (R/M HNSCC) is a
devastating malignancy with a poor prognosis. Treatment is limited to chemotherapeutic …
devastating malignancy with a poor prognosis. Treatment is limited to chemotherapeutic …
Multi institutional phase II study of concomitant stereotactic reirradiation and cetuximab for recurrent head and neck cancer
EF Lartigau, E Tresch, J Thariat, P Graff… - Radiotherapy and …, 2013 - Elsevier
Purpose Recurrent head and neck cancer is associated to a poor survival prognosis. A high
toxicity rate is demonstrated when surgery and/or radiotherapy and/or chemotherapy are …
toxicity rate is demonstrated when surgery and/or radiotherapy and/or chemotherapy are …
Systemic treatment and medical management of metastatic squamous cell carcinoma of the head and neck: review of the literature and proposal for management …
F Peyrade, D Cupissol, L Geoffrois, F Rolland, C Borel… - Oral oncology, 2013 - Elsevier
OBJECTIVE: Worldwide, head and neck carcinomas account for 5% of all malignancies.
Two-thirds of patients relapse after initial multimodal therapy. Until early 2000, the median …
Two-thirds of patients relapse after initial multimodal therapy. Until early 2000, the median …
Design of a phase I clinical trial to evaluate intratumoral delivery of ErbB-targeted chimeric antigen receptor T-cells in locally advanced or recurrent head and neck …
MCI van Schalkwyk, SE Papa, JP Jeannon… - Human gene therapy …, 2013 - liebertpub.com
Despite several advances, 5-year survival in patients with head and neck squamous cell
carcinoma (HNSCC) remains unchanged at only 50%. The commonest cause of death is …
carcinoma (HNSCC) remains unchanged at only 50%. The commonest cause of death is …
[HTML][HTML] Phase II study of sorafenib in combination with cisplatin and 5-fluorouracil to treat recurrent or metastatic nasopharyngeal carcinoma
C Xue, Y Huang, PY Huang, QT Yu, JJ Pan, LZ Liu… - Annals of oncology, 2013 - Elsevier
Background We aimed to investigate the efficacy and tolerability of sorafenib combined with
cisplatin and 5-fluorouracil (5-FU) in patients with recurrent or metastatic nasopharyngeal …
cisplatin and 5-fluorouracil (5-FU) in patients with recurrent or metastatic nasopharyngeal …
Phase II 2‐arm trial of the proteasome inhibitor, PS‐341 (bortezomib) in combination with irinotecan or PS‐341 alone followed by the addition of irinotecan at time of …
J Gilbert, JW Lee, A Argiris, M Haigentz Jr… - Head & …, 2013 - Wiley Online Library
Background Constitutive activation of nuclear factor κB (NF‐κB) is associated with poor
prognosis. Irinotecan demonstrates single‐agent activity in head and neck cancer but …
prognosis. Irinotecan demonstrates single‐agent activity in head and neck cancer but …
Advances in the management of recurrent or metastatic squamous cell carcinoma of the head and neck
Most patients with locally advanced squamous cell carcinoma of the head and neck
(SCCHN) undergo definitive therapy, yet locoregional recurrence and metastasis are …
(SCCHN) undergo definitive therapy, yet locoregional recurrence and metastasis are …
Multidisciplinary care of the patient with head and neck cancer
V Saloura, A Langerman, S Rudra… - Surgical Oncology …, 2013 - surgonc.theclinics.com
Head and neck cancer (HNC) comprises a heterogeneous group of cancers, which primarily
affect the oral cavity, oropharynx, hypopharynx, larynx, and nasopharynx. In 2010, HNC was …
affect the oral cavity, oropharynx, hypopharynx, larynx, and nasopharynx. In 2010, HNC was …
Phase Ib trial of the Toll-like receptor 9 agonist IMO-2055 in combination with 5-fluorouracil, cisplatin, and cetuximab as first-line palliative treatment in patients with …
JP Machiels, MC Kaminsky, U Keller… - Investigational new …, 2013 - Springer
Summary Background This Phase Ib trial assessed the maximum tolerated dose (MTD) and
safety of the Toll-like receptor 9 agonist IMO-2055 combined with 5-fluorouracil, cisplatin …
safety of the Toll-like receptor 9 agonist IMO-2055 combined with 5-fluorouracil, cisplatin …